OBI Pharma, Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2002)

Organization Overview

First Clinical Trial
2011
NCT01516307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AP Biosciences Inc. | OBI Pharma, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

adagloxad simolenin (4 trials)

Drugs in Phase 2 Trials (6)

ap203 (1 trial)

cyclophosphamide (cytoxan) (1 trial)

erlotinib (tarceva) (1 trial)

obi-3424 (1 trial)

obi-999 (1 trial)

saponin (1 trial)

Drugs in Phase 1 Trials (2)

obi-833 (1 trial)

obi-888 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9